Android app Apple app link

FDA awards ODD status to Sanofi's rilzabrutinib for two rare conditions

By Yahoo! Finance   |   3 weeks ago
FDA awards ODD status to Sanofi's rilzabrutinib for two rare conditions

Sanofi's rilzabrutinib, a BTK inhibitor, received FDA orphan drug designation for treating IgG4-related disease and warm autoimmune haemolytic anaemia. Promising results from Phase II trials show potential benefits for patients.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

To become a member, please download and purchase membership through our app.